Are these new hair loss treatments ever gonna release? 3/29/2026
Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?
Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.
community Minoxidil alone, 4 months consistent usage
Minoxidil 5% foam was used twice daily for 4 months, resulting in visible hair regrowth. Users discussed adding finasteride for better long-term results, with concerns about its side effects and alternatives like breezula and clascoterone.
community Will Breezula simply be an overhyped flop?
Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.
community Is this sub gonna accept that PP405 is a nothingburger? Or do we wait 5 more years?
The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.
community Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
Related Research
6 / 6 resultsresearch Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research 0951 Breezula, a clinical stage topical anti-androgen, promotes dermal papilla inductivity and reduces IL-6 secretion in balding skin samples ex vivo
This study suggests that Breezula® and Minoxidil both enhance hair growth in male pattern hair loss by promoting keratinocyte proliferation, with Breezula® potentially more potent in reducing the hair growth inhibitor IL-6.
research Androgenetic Alopecia: An Update of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research New drugs under investigation for the treatment of alopecias
This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.
research Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options
This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.